162 related articles for article (PubMed ID: 8376592)
41. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus.
Avalos I; Chung CP; Oeser A; Milne GL; Borntrager H; Morrow JD; Raggi P; Solus J; Stein CM
Lupus; 2007; 16(12):981-6. PubMed ID: 18042592
[TBL] [Abstract][Full Text] [Related]
42. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
43. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
44. Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation.
Livingston ER; Fisher CA; Bibidakis EJ; Pathak AS; Todd BA; Furukawa S; McClurken JB; Addonizio VP; Jeevanandam V
Circulation; 1996 Nov; 94(9 Suppl):II227-34. PubMed ID: 8901751
[TBL] [Abstract][Full Text] [Related]
45. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests.
Gresele P; Catalano M; Giammarresi C; Volpato R; Termini R; Ciabattoni G; Nenci GG; Davì G
Thromb Haemost; 1997 Dec; 78(6):1434-7. PubMed ID: 9423790
[TBL] [Abstract][Full Text] [Related]
46. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
47. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites.
Forastiero R; Martinuzzo M; Carreras LO; Maclouf J
Thromb Haemost; 1998 Jan; 79(1):42-5. PubMed ID: 9459320
[TBL] [Abstract][Full Text] [Related]
48. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
49. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.
Petrucci G; Giaretta A; Ranalli P; Cavalca V; Dragani A; Porro B; Hatem D; Habib A; Tremoli E; Patrono C; Rocca B
Clin Transl Sci; 2022 Dec; 15(12):2958-2970. PubMed ID: 36200184
[TBL] [Abstract][Full Text] [Related]
50. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
51. Oxidative stress and platelet activation in homozygous homocystinuria.
Davì G; Di Minno G; Coppola A; Andria G; Cerbone AM; Madonna P; Tufano A; Falco A; Marchesani P; Ciabattoni G; Patrono C
Circulation; 2001 Sep; 104(10):1124-8. PubMed ID: 11535567
[TBL] [Abstract][Full Text] [Related]
52. Insulin resistance as a determinant of platelet activation in obese women.
Basili S; Pacini G; Guagnano MT; Manigrasso MR; Santilli F; Pettinella C; Ciabattoni G; Patrono C; Davì G
J Am Coll Cardiol; 2006 Dec; 48(12):2531-8. PubMed ID: 17174194
[TBL] [Abstract][Full Text] [Related]
53. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Eikelboom JW; Hankey GJ; Thom J; Bhatt DL; Steg PG; Montalescot G; Johnston SC; Steinhubl SR; Mak KH; Easton JD; Hamm C; Hu T; Fox KA; Topol EJ;
Circulation; 2008 Oct; 118(17):1705-12. PubMed ID: 18838564
[TBL] [Abstract][Full Text] [Related]
54. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
55. Determinants of platelet activation in Alzheimer's disease.
Ciabattoni G; Porreca E; Di Febbo C; Di Iorio A; Paganelli R; Bucciarelli T; Pescara L; Del Re L; Giusti C; Falco A; Sau A; Patrono C; Davì G
Neurobiol Aging; 2007 Mar; 28(3):336-42. PubMed ID: 16442186
[TBL] [Abstract][Full Text] [Related]
56. Estimation of thromboxane B2 in the clotting human whole blood by gas chromatography.
Block HU; Sziegoleit W; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S385-8. PubMed ID: 6517904
[TBL] [Abstract][Full Text] [Related]
57. Determinants of enhanced thromboxane biosynthesis in renal transplantation.
Averna M; Barbagallo CM; Ganci A; Giammarresi C; Cefalù AB; Sparacino V; Caputo F; Basili S; Notarbartolo A; Davì G
Kidney Int; 2001 Apr; 59(4):1574-9. PubMed ID: 11260423
[TBL] [Abstract][Full Text] [Related]
58. [The effect of peripheral blood mononuclear cell products from children with nephrotic syndrome on thromboxane A2 metabolism].
Watanabe Y; Suzui J; Ichikawa Y; Yoshida K; Suzuki H
Arerugi; 1995 May; 44(5):547-55. PubMed ID: 7619008
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.
Davì G; Patrono C; Catalano I; Custro N; Giammarresi C; Ganci A; Cosentino F; Notarbartolo A
Arterioscler Thromb; 1993 Sep; 13(9):1346-9. PubMed ID: 8364018
[TBL] [Abstract][Full Text] [Related]
60. Defective aggregation in cirrhosis is independent of in vivo platelet activation.
Laffi G; Cinotti S; Filimberti E; Ciabattoni G; Caporale R; Marra F; Melani L; Grossi A; Carloni V; Gentilini P
J Hepatol; 1996 Apr; 24(4):436-43. PubMed ID: 8738730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
